Summit plc begins phase I clinical trial in seborrhoea

25-Oct-2007

Summit Corporation plc announced the commencement of a Phase I clinical trial of SMT D002 for the treatment of seborrhoea (excessive sebum production), a symptom of Parkinson's disease and the primary cause of acne.

The recruitment of 18 healthy volunteers for the trial is complete with dosing now underway; treatment is expected to last for five weeks. The study will examine the effects of repeat oral doses of SMT D002 on sebum excretion rates and thereby add to results of an earlier double-blind Phase I study in healthy volunteers using a single oral dose that showed up to a 70% reduction in sebum excretion. Summit expects to report the results from this new study during Q1 2008.

In addition to treating seborrhoea in Parkinson's disease, Summit believes that SMT D002 also has potential use in other therapeutic areas, particularly acne where a reduction in sebum levels would be beneficial. SMT D002 would represent a brand new treatment for acne and future studies planned under its programme in both areas will assess the potential of SMT D002 in a topical formulation as well as oral, in order to establish proof of concept and to create an attractive commercial offering for out-licensing.

SMT D002 has been developed using Summit's drug reprofiling expertise whereby the Company has identified these new indications in Parkinson's disease and acne for a marketed, off-patent small molecule drug that has a long, established history of safe use. The Company has a strong patent position to protect the use of SMT D002 in these new indications.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

BASF and Embrapa’s Cultivance soybeans receive approval for commercial cultivation in Brazil - First genetically modified crop developed in Brazil to reach commercialization stage

Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched

FDA grants cardiotrophin-1 Orphan Drug status for acute liver failure treatment to Digna Biotech

Pioneering research succeeds in producing industrially vital chemical through engineered bacteria - Metabolic engineering could herald the end of fossil fuels in industrial chemical production

Merck to manufacture liquid biopsy kits for Swedish start-up - Liquid biopsy kits aim to improve accuracy of cancer diagnosis

Merck to manufacture liquid biopsy kits for Swedish start-up - Liquid biopsy kits aim to improve accuracy of cancer diagnosis

What influences the success of founders - Outstanding dissertation in the field of entrepreneurship honoured

What influences the success of founders - Outstanding dissertation in the field of entrepreneurship honoured

BASF sells marine biopolymers business to Seagarden ASA

'Living' biofilters could reduce greenhouse gas emissions - Naturally occurring microscopic organisms could cut emissions from Alberta industries

ThromboGenics Opens New U.S. Headquarters - U.S. Organization Continues to Build Ahead of Ocriplasmin’s Planned Launch

Researchers work to create biodegradable bioplastics from food waste - Use of microorganisms to convert food waste into fats, which are then processed into bioplastics

Researchers work to create biodegradable bioplastics from food waste - Use of microorganisms to convert food waste into fats, which are then processed into bioplastics

Evotec and LEO Pharma form drug discovery alliance targeting dermatological conditions

Adventus Group Establishes Joint Venture for European Expansion with S&B Industrial Minerals